Universal Ibogaine Inc.
IBO.V
Get informed when a big investor buys or sells
+ FollowMarket Cap$1.56M
Close$
Share Statistics
| Market cap | $1.56 Million |
|---|---|
| Enterprise Value | $4.42 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-0.01 |
| Beta | 4.38 |
| Outstanding Shares | 308,610,516 |
Return
| Return on Equity | -542.44% |
|---|---|
| Return on Assets | -36.85% |
| Return on Invested Capital | -36.03% |
Valuation & Multiples
| P/E Ratio | -0.5 |
|---|---|
| PEG | 0.54 |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | 2.14 |
| Enterprise Value to EBIT | -6.15 |
| Enterprise Value to Net Income | -3 |
| Total Debt to Enterprise | 0.67 |
| Debt to Equity | 10.96 |
Revenue Sources
No data
Insider Trades
Institutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Universal Ibogaine Inc.
7 employees
CEO: Nicholas Peter Karos Universal Ibogaine Inc., a life sciences enterprise, focuses on developing, acquiring, and operating addiction treatment centers across Canada. The company is additionally preparing to launch clinical trials aimed at researching ibogaine...